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Upper limb spasticity management for patients who have received Botulinum 
Toxin A injection: Australian therapy practice 
Abstract 
Background/aim To describe Australian physiotherapy and occupational therapy practice for patients who 
receive upper-limb Botulinum Toxin-A (BoNT-A). Method Anonymous online survey asking about practice 
experience. Convenience sample of 128 BoNT-A experienced occupational therapists and 
physiotherapists. Results The primary work setting was multidisciplinary inpatient or outpatient 
rehabilitation services where therapists had automatic referral to BoNT-A patients. Patients expected 
BoNT-A to improve functional movement, reduce hypertonicity, increase passive range, reduce pain, 
improve appearance and hand hygiene. Most patients were injected in multidisciplinary public hospital 
clinics and had median 2 pre-injection (range 0-30) and 8 post-injection (range 0-50) therapy sessions. 
Biceps, flexor digitorum profundus/superficialis and brachoradialis were most frequently injected. 
Injectors used therapist assessment information to select sites 68% of the time; only 44% of services had 
assessment protocols. Standardised therapy assessments examined motor performance, pain and 
function in that order of frequency. The greater the awareness and perceived relevance of an assessment 
the more often therapists used it. All therapists set goals, most collaboratively, and these mirrored patient 
expectations. The most common treatments were stretch, task-specific functional training, strength 
training and home programmes. Conclusion While trends in Australian assessment, goals and treatment 
practice were observed, greater consistency could be achieved if therapy practice guidelines existed. The 
gap is exacerbated by the absence of Australian BoNT-A organisation and process of care spasticity 
management guidelines. This creates an environment where practice variability is inevitable. 
Recommendations to improve local service quality are made. 
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INTRODUCTION 
Upper limb spasticity is a common consequence of neurological events such as stroke. 
Spasticity is “a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes 
(muscle tone) with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex” 
(Lance,1980,p.485). It emerges over time (Lundström, Smits, Terént, & Borg,2010), and can have 
devastating effects on quality of life through associated pain, limitations to passive and active 
movement, threats to skin integrity, difficulties in self-care and limb hygiene and in the long term, the 
potential for fixed contracture (Kong, Chua, & Lee,2010; Stevenson,2010). Traditional occupational 
therapy and physiotherapy approaches to spasticity management have, more recently, been 
augmented by pharmacotherapy such as Botulinum toxin –A (BoNT-A) injections. BoNT-A has been 
demonstrated to be safe and effective in reducing focal  spasticity in a range of neurological conditions 
(Delgado, Hirtz, Aisen et al.,2010; Muller, Cugy, Ducerf et al.,2012; Simpson, Gracies, Graham et 
al.,2008). In Australia, the National Stroke Foundation (NSF) does not recommend BoNT-A for 
everyone with spasticity, rather, for those patients who have persistent moderate to severe spasticity 
that “interferes with activity or personal care” (NSF,2010)(Guide 7.3b).  BoNT-A injection for post-stroke 
upper limb spasticity in Australia is subsidized through the government Pharmaceutical Benefits 
Scheme (PBS) “S100 Botulinum Toxin Program criteria for availability”. To be eligible a patient with 
upper limb post-stroke spasticity requires an:-  
“MAS greater than or equal to 3 using modified Ashworth scale …as second line therapy when 
standard management has failed … or as an adjunct to physical therapy … [BoNT-A] treatment 
should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at 
least one joint) after two treatments” (Department of Human Services Australian Government, 
2012).   
Injection can only be done by a medical practitioner in Australia and this is usually a neurologist or 
rehabilitation physician.  
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BoNT-A for spasticity management can be used in isolation but researchers and peak 
rehabilitation bodies recommend  multidisciplinary organisation of services and processes for care 
(Ozcakir & Sivrioglu,2007; Quinn, Paolucci, Sunnerhagen et al.,2009; Royal College of Physicians, 
British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered 
Physiotherapists Interested in Neurology,2009; Sheean et al., 2010; Turner-Stokes & Ward 2009; 
Wissel, Gracies, Graham et al.,2008).  Multidisciplinary BoNT-A spasticity management processes of 
care should include the following elements:  managing patient expectation, developing functional goals, 
using treatment plans and outcome measures, ensuring post-injection therapy review, implementing 
post-review treatment planning and providing self-management support (Allison & Knapp,2012). To 
date little information about processes of care as evidenced by practice patterns is available (eg., 
Williams, Olver, De Graff, & Singer,2012 is the only study to date on Australian therapy BoNT-A related 
practice); and as yet practice guidelines for BoNT-A related therapy assessment and treatment have 
not been developed (Levy, Giuffrida, Richards et al.,2007; Sun, Hsu, Sun et al.,2010; Weber, Skidmore, 
Niyonkuru et al.,2010). Evidence regarding post-stroke treatment effects in multidisciplinary spasticity 
management is also limited (Demetrios, Khan, Turner-Stokes, Brand & McSweeney,2013). This study 
helps fill these evidence gaps by exploring BoNT-A related therapy practice in Australia, augmenting 
previous work (Williams et al., 2012), by extending enquiry into factors relating to the organisation and 
process of care including injection and therapy settings, referral arrangements, muscles injected, 
assessments used and goal setting. Background information relating to these factors is now briefly 
reviewed.  
Muscles injected: Currently, there are no Australian BoNT-A spasticity management guidelines 
to inform physician injection decisions. The Australasian Faculty of Rehabilitation Medicine 
(AFRM)(2009a) has only one position statement relating to use of BoNT-A (AFRM,2009b); this dates 
back to 1997 and it is not specific to spasticity management in adults. Although international BoNT-A 
spasticity management guidelines are available, the AFRM does not appear to have appraised or 
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endorsed them. Australian injectors therefore set their own BoNT-A spasticity management standards 
and determine their own processes for site selection and post-injection follow-up.   Injector preference, 
not factors such as patient goals or severity of spasticity, have been shown to underpin BoNT-A muscle 
site selection in Australia (Baguely, Nott, Turner-Stokes et al.,2011).  
 Goals and Goal setting: Spasticity management should be goal directed and these goals 
should address function (NSF, 2010; Quinn et al.,2009; Royal College of Physicians et al,2009; Sheean 
et al.,2010; Turner-Stokes & Ward,2009; Wissel et al.,2010).  Goal-setting that involves patients, 
carers, therapists and physicians is also recommended (Allison & Knapp,2012; Royal College of 
Physicians et al.,2009).  Goal types can differ in frequency depending on spasticity recovery stage 
(Bakheit, Zakine, Maisonobe et al.,2010; Royal College of Physicians et al.,2009; Williams et al.,2012). 
In the early months of recovery the most common goal for BoNT-A treatment is active functional 
recovery, but in chronic spasticity management  it is passive function. Pain relief is a common goal in 
both early and chronic spasticity conditions.    
Assessments: Assessment should help inform goal setting and evaluation of goal attainment.  
Standardised functional assessments are however, rarely used in BoNT-A related therapy (Bakheit et 
al.,2010; Williams et al.,2012). Instead, one Australian study found goal achievement was measured 
through patient or family self-report, standardised outcome measures that may not reflect activities of 
daily living, or non-standardised assessments (Williams et al.,2012).  
Treatment modalities: Therapy treatment for BoNT-A patients includes physical modalities 
(such as sustained stretch using serial casting, orthoses, taping/strapping), strengthening, forced use 
motor training (constraint-induced movement therapy), repetitive task specific practice and/or mental 
practice, “movement based therapy”, home exercise programs, electrical stimulation to agonist and 
injected muscles, and adaptation of activities or the environment to prevent and minimize adverse 
impact of spasticity on function (Ada, Dorsch, & Canning,2006; Demetrios et al.,2013; Katalinic, Harvey, 
Herbert et al.,2010; Page, Murray, & Hermann,2011; Treger, Aidinof, Lehrer, & Kalichman,2012; 
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Williams et al.,2012). Currently there are no modality-specific guidelines for treatment type, frequency 
or duration, nor is much known about current practice. Evidence of multidisciplinary rehabilitation effect 
is considered limited in scope and of low quality (Demetrios et al.,2013). To date there has been debate 
about BoNT-A’s contribution to attainment of functional goals (Caty, Detrembleur, Bleyenheuft et 
al.,2009; Cousins, Ward, Roffe et al.,2001; Delgado et al.,2010; Francis, Wade , Turner-Stokes et 
al.,2004; Galvin & Sakzewski,2011; Lai, Francisco, & Willis,2009; Patel,2011; Rosales, Kong, Goh et 
al.,2002). At the same time there has been promising evidence that  BoNT-A plus therapy  may have 
sustained positive effects in spasticity reduction (Katalinic et al.,2010; Wolf, Milton, Reiss et al.,2012) 
and functional outcomes (Ada et al.,2006; Page et al.,2011; Treger et al.,2012).  
    
METHODS 
This study aims to describe current Australian spasticity management practice by outlining the 
organisation and processes of care from a therapist perspective. To do this, an online anonymous self-
report survey was conducted with therapists who responded to a study invitation distributed through 
informal neuro-rehabilitation occupational therapy and physiotherapy networks in Australia. Recruitment 
took place after approval of researcher institutional research ethics committees.  The study invitation 
specified that participants needed to be working in Australia, have upper limb neurological rehabilitation 
experience in the past five years, and experience working in services where patients had received 
BoNT-A injections.  
 The author-designed survey asked demographic and clinical experience questions. 
Organisation of BoNT-A care was explored through questions about: proportion of neuro-rehabilitation 
caseload that received BoNT-A, injection setting, referral process, patient access to therapy, therapy 
setting and service type. Processes of BoNT-A therapy care were examined by questions about: patient 
expectations; muscles injected; assessments used (rated as: not heard of it, never, rarely, sometimes, 
often, always); assessment relevance  (rated as: don’t know, essential must be included important, 
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acceptable, marginal, not relevant shouldn’t be included)(scale adapted from Clemson, Fitzgerald & 
Heard,1999; Skakun & King,1980); injector use of assessment information in site selection; whether or 
not the service had an assessment protocol; goal-setting; goals set (rated on: never, rarely, sometimes, 
often always); and  treatment modalities used (rated on: never, rarely, sometimes, often, always). Even 
though BoNT-A cannot reduce contracture this was included in the goal questions because anecdotally 
it was reported to be in use.  
Responses were submitted by participants into Survey Monkey™ and data was imported to 
SPSS Version 20 (IBM, 2011). A value was allocated to Likert-type responses (higher values to higher 
ratings; not heard of it and don’t know reported separately); item values were summed and then ranked 
to show trends.  Comments were invited regarding other goals and whether or not all patients who 
receive BoNT-A receive therapy. Comments with the same or similar wording were grouped together so 
the range of the responses could be reported. In the case of patient expectations, the number of 
responses in each category was tallied to show trends. No question in the survey was compulsory. 
Missing items are noted in the text or tables.  
RESULTS 
All participants (n=128) were university qualified; aged between 23 and 60 years (mean 33.5; median 
32; SD 7.8). They were predominantly female occupational therapy clinicians working in capital cities in 
inpatient or outpatient rehabilitation services (Table 1). Only 27.9% (n=33) worked some or all of the 
time in a BoNT-A clinic (n=85, 72% did not; n=10 missing). Most had worked with 10 or less BoNT-A 
injection patients in their career and 10% or less of their neurology caseload were injected patients. 
Overall, participants (n=127) had significant total career (mean 11.5, median 10, SD8.1, range 1.5 to 40 
years) and neurology (mean 8.9, median 7, SD7.8, range 7 months to 35 years) clinical experience. For 
most of the n=122 respondents, years of BoNT-A experience were less than half that of their neurology 
experience (mean 4.12, median 3, SD3.26, range 3 months to 15 years). In the past 12 months, 91.4% 
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had seen neurological patients who had received upper limb BoNT-A injections and 58.6% had current 
BoNT-A patients. 
Organisation of care  
Overwhelmingly, BoNT-A injections were provided in public hospital BoNT-A spasticity management 
clinics (72%), with half of the patients receiving injections in multidisciplinary services (49.5%); a quarter 
were given in physician-only services (28.5%)(Table 2).   Most therapists (58.5%) reported they could 
choose when they saw injected patients.  Setting-specific automatic therapy referral known as “blanket 
referral” accounted for 23% (Table2). Participants were asked whether they thought all patients who 
had received BoNT-A injections received therapy and most said “no” (n=68 of 81 respondents; 84%). 
Participants commented on issues they thought related to therapy access (Table 3); timely referral and 
team communication were important. 
Process of care 
Injections: Therapists reported most of their BoNT-A patients were ‘first –time’ BoNT-A 
recipients, (only 34% had repeat injections). Of 26 different upper limb muscles, participants reported 
that biceps, flexor digitorum profundus/ superficialis and brachoradialis were the most frequently 
injected (Table 4). Those muscles at the top of the ‘never injected’ list were in descending order, 
rhomboids, extensor digitorum,and extensor carpi ulnaris. The muscles most often ‘not known’ about by 
therapists were levator scapulae and subscapularis.    
Assessments: Most participants reported their clinic/workplace did not have assessment 
protocol they had to use (47.5%, n=61), 37% did (n=48) (n=19, 15% missing); but the overwhelming 
majority did assess their patients (all but 6 of 90 respondents;  n=38 missing) before and after injection 
(n=60,67%).. Most therapists thought physicians used their assessment findings always or sometimes 
to select injection sites (n=61, 67.7%). Assessment awareness and frequency of use is presented in 
Table 5(footnote includes citations). All had heard of range of motion/goniometry, only one had not 
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heard of the Modified Ashworth Scale or Ashworth Scale, two the manual muscle test, Barthel Scale 
and Motor Assessment Scale, and three the Goal Attainment Scale. The most frequently used 
assessments in order were range of motion (highest), next Modified Ashworth Scale, the Tardieu, 
Manual Muscle test, Modified Tardieu Scale, Motor Assessment Scale, the Pain Visual Analogue Scale, 
and then Goal Attainment Scaling. In general terms, greater use mirrored greater assessment 
awareness and perceived relevance. 
Patient expectations: N=104 respondents described what they thought patients expected from 
their BoNT-A injection. In order from most to least frequent they were “active/functional movement/ 
dexterity” (n=43; 41.3%), improvement in hypertonicity/ tightness (n=19; 18.3%), increased passive 
range (n=18, 17.3%), reduction in pain (n=16; 15.4%), enhanced appearance (n=12, 11.5%), and 
improved hygiene (n=9, 8.6 %).    
Goals: Participants (n=83; 45 missing) set goals either with (97.6%, n=81) or independent of 
(2.4%, n=2) patients and just over half of all patients had goals set before they were injected. There 
was a pattern in goal use: least used was increased upper limb dexterity, in increasing frequency was 
enhanced occupational therapy or physical therapy,enhanced cosmetic appearance of the upper limb, 
reduced contracture, increased upper limb active movement, reduced pain, and enhanced hygienic 
care was the most frequently used. N=47 participants identified other goals: the most frequent one, 
“enhanced function”, was usually qualified with the descriptor “task specific”. Some participants gave 
examples of these tasks (eg., dressing) or indicated that tasks were identified by patients. Other goals 
were: (a) to enhance position or posture, upper limb movement patterns, repetitive reciprocal exercise, 
tolerance of and ability to wear orthoses, balance and gait safety and/or sleep through decreased pain; 
(b) maintain range of movement and/or joint integrity; (c) prevent contracture deterioration; and (d) 
decrease care-giver burden.  
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Treatment modalities: Nine treatment modalities were rated from never to always used (n=85; 
43 missing). In order from low to high use they were: biofeedback, orthotic casts, electrical stimulation/ 
functional electrical stimulation, orthotic splints, movement training, home programs, strength training, 
task specific functional training and stretch. Sixteen therapists reported they used other treatments (a) 
constraint induced movement therapy, (b) task and strength movement training, (c) weight bearing 
stretches, (d) therapeutic positioning, (e) general fitness program and (f) compensation training for 
functional activities  
Treatment session frequency: Most patients were reported to receive pre-injection (mean 
3.8,median 2, SD5.99, range 0 to 30 sessions; n=18, 24% had  no pre-injection therapy) and post-
injection sessions (mean 10.2,median 8, SD9.57, range 0 to 50; n=6, 5.6% had no post-injection 
therapy). To calculate the number of therapy sessions the following decision rules were used because 
participants answered the question in a variety of ways. In the case of pre-injection therapy sessions: 
(a) n=67 participants gave a numerical estimate which was used; (b) n=5 gave a range and in this case 
the highest or the highest aggregate was used, eg. “1-6” was reported as 6 sessions while “1-6 weeks 
of 3-5 sessions/week” was  reported as the function of 6 weeks by 5 sessions per week thus 30 
sessions; (c) n=6 gave a weekly range eg., “3-5 per week”, but because the number of weeks was not 
specified, a total could not be estimated so data was treated as missing;(d) n=31 gave no estimate but 
instead gave a description such as “variable/varies”=13,  “daily”=5, “depends”=3, or some other 
word=10 such as “routine”, “lots”, “many”, “several” and these were also treated as missing data; (e) 
n=19 did not answer. Thus 56 of 128 pre-injection therapy responses were treated as missing data. In 
the case of post-injection therapy sessions the same ‘rules’ applied: (a) n=44 gave a numerical 
estimate; (b) n=25 gave a range; (c) n=9 gave a weekly range but did not specify number of weeks; (d) 
n=26 gave a descriptor instead of an estimate eg., “variable/varies”=5, “depends”=4;; (e) n=24 did not 
answer. Thus 59 of 128 post-therapy responses were treated as missing data. 
DISCUSSION 
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At present Australian therapists must practice in the absence of national BoNT-A spasticity 
management guidelines and without therapy-specific guidelines in particular. This is a challenge given 
our findings that BoNT-A therapy was both exceptional and relatively new for most therapists. 
‘Exceptional’ in that most therapists had seen few BoNT-A patients in their careers and the proportion 
of their caseload receiving BoNT-A was small. ‘New’ in that most therapists had BoNT-A years of 
experience that were less than half that of their neurology practice. The practice variability we observed 
may be a consequence of this infrequent and relatively new exposure. But equally it may result from 
varying local approaches to care developed without AFRM guidance regarding ‘model’ processes and 
organizational arrangements for multidisciplinary care. One participant comment illustrates current 
gaps:- 
Most adult patients I have had experience with rarely see a therapist pre-injection. They also rarely 
receive post-injection therapy. If patients do have access to therapy services it is extremely uncommon 
that the therapist has the required skills to provide appropriate interventions such as casting, splinting 
and movement based interventions. The most significant issue is related to the model of service 
delivery for adults with a disability. Patient follow-up and monitoring over time is completely inadequate 
and patients are given their immediate post injection therapy and discharged. This is not appropriate for 
this patient population as their complex impairments need ongoing review and intervention  
Australian guidelines for BoNT-spasticity management and therapy specific guidelines are urgently 
required. Guidelines will provide a national benchmark for local practice improvement. Meanwhile 
therapists can improve their own process of care through professional development and consider 
implementing quality improvement activities to enhance local organization of care. The following 
recommendations provide a starting point for change.  
This study demonstrated that most of the time, spasticity management was through 
multidisciplinary ‘shared care’ (NSF,2010; Wissel et al.,2008). But a minority reported this NSF 
recommendation was not implemented, with physicians injecting without referring to therapy, or the 
absence of a coordinated goal directed approach (Royal College of Physicians et al.,2009; Sheean et 
al.,2010). Multidisciplinary team communication, a feature of good quality care (NSF Guide 1.8) was 
also reported to be problematic in a minority of services, particularly in relation to physician-therapist-
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patient communication about patient expectations, functional goals, and injection site selection and 
follow up. The AFRM identifies a key function of rehabilitation physicians is to provide “coordinated and 
patient-focused program[s] of individual, goal directed rehabilitative care” (AFRM, 2009c). Team 
communication would appear to be central to achieving this. Local strategies targeting team 
communication could be implemented to help physicians fulfil the coordination  function in relation to 
BoNT-A spasticity management.   
There is promising evidence that BoNT-A plus therapy achieves positive results (Ada et 
al.,2006; Katalinic et al.,2010; Page et al.,2011; Treger et al.,2012; Wolf, Milton, Reiss et al.,2012), but 
participants reported that injected patients do not always receive therapy. Local strategies to encourage 
and streamline therapy referral should be developed. Service organization could be improved by 
providing sufficient therapy resources to meet demand of BoNT-A injected patients. If therapy cannot 
be provided, services need to consider whether funds spent on BoNT-A alone are a wise spasticity 
management investment.   
Services also need to consider whether the timing and amount of therapy they provide is 
appropriate and adequate. The NSF Guide 6.1.1a (NSF, 2010) recommends as much practice as 
possible within the first six months of stroke, unfortunately our study did not examine when therapy 
occurred in relation to the stroke. NSF Guide 6.1.1b (NSF, 2010) recommends at least one hour 
therapy per day at least five days a week for patients in ‘active rehabilitation’; unfortunately our study 
did not examine service arrangements for therapy sessions. But our study did obtain an estimate of the 
number of therapy sessions patients typically received which was pre-injection mean 3.8 (median 2) 
post-injection mean 10.2 (median 8) and a quarter of participants reported no pre or post therapy. 
Services should ensure that the number of pre- and post-injection therapy sessions, their timing in 
relation to the stroke event and their duration is monitored to help build an evidence base for future 
investigation. 
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Processes of care could be improved at a local level through development of service protocols 
for referral, assessment, site selection, goal setting, treatment and follow-up. Timing and type of referral 
varied in this study; greater consistency could minimize barriers to patient access to therapy when it is 
available.  Injector use of assessment findings also varied – some chose sites unrelated to assessment 
findings and goals. Service protocols that encourage a link between assessment findings, 
collaboratively developed functional goals (Royal College of Physicians et al.,2009; NSF Guide 1.4.2b ; 
Wissel et al.,2008; Turner-Stokes et al., 2009) and injection  site selection would help facilitate a patient 
centered approach to spasticity management.    
Processes of care could also be improved through professional development. Most services did 
not have assessment protocols and some participants did not use standardized assessments. While all 
participants set goals and most were functional, not all used functional assessments. The most 
frequently used assessments encompassed motor performance followed by pain and function. Greater 
use of standardized assessments, and functional assessments in particular would improve evidence-
based decision-making and goal setting. Professional development may be required to enhance 
therapist knowledge of and skill in standardized functional assessment selection, administration and 
interpretation. This could be supported by service adoption of assessment protocols. One assessment 
illustrates the urgent need for professional development in assessment knowledge and skill. When 
compared with Williams et al. (2012) our sample had better uptake of the MAS, as only 45.7% of their 
sample used it. But given the critical role of the MAS as a threshold measure for PBS subsidy it would 
be expected that 100% of therapists should have used it and this was not the case. Australian 
therapists have previously reported their BoNT-A training was ad-hoc, gained through “lecture, seminar 
or workshop [attendance] related to Botulinum toxin injections and spasticity management” (Williams et 
al., 2012, p.259). This further reinforces the need for targeted professional development. 
Processes of care could also be improved by services developing local treatment protocols and 
professional development to enhance therapist capacity in administering treatment modalities. The 
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most common interventions in this study were recommended modalities: stretch (Demetrios et 
al.,2013), strength training  (Guide 6.2.2), movement training and task-specific functional training  
(Guide 6.3.5a and b; Guide 6.4b), but consistency in approach is lacking without therapy guidelines. 
Local treatment protocols may fill that gap. Home programs were also common but as a modality they 
are opaque: services need to make explicit what is in them, frequency, duration and intensity 
particularly in relation to NSF Guides 6.1.1e and 6.3.5a that relate to practice. Services can also 
describe why some recommended treatments are not used. CMIT, for example is supported by the NSF 
Guide 6.3.5a, but barriers to use have been identified (Viana & Teasell, 2012).   
Limitations: This study was limited by the self-report, anonymous and convenience sampling 
design. The survey itself brought limitations because it was not standardized and subsequent analysis 
of results has revealed gaps and problems in data coding that weaken the study. While all therapists 
provided demographic and most provided clinical setting responses, there were many missing 
responses – especially at the point in the survey where participants were asked to use Likert-type 
scales to rate multiple items. Between a quarter and a third of participants did not respond to ratings 
even though all participants continued “clicking through” survey pages so they could submit. Response 
drop may have been due to responder fatigue, time pressures, or questions could have been difficult to 
answer if participants were not aware of organization of services at their workplace, or if they or their 
service did not know about or use the range of assessments, goals and treatments identified.  
In conclusion, although BoNT-A therapy practice varies in Australia, trends were evident. On 
the whole, if patients are referred for  therapy, most will have a multidisciplinary team providing 
coordinated care in a publicly funded inpatient or outpatient rehabilitation setting. Patients will have 
treatment goals set collaboratively, and these will reflect patient expectations and will focus on function. 
Standardized assessments will normally be used and assessments will collect information about patient 
motor performance, pain and function. Most patients will have home programs, but we don’t know what 
these entail. Patients will receive therapy treatments that are generally consistent with NSF 
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recommendations; however interventions lack strong evidence of effect. On the whole patients will 
receive more therapy sessions after injection than before, but more research is needed regarding 
session timing, frequency and duration. Development of Australian spasticity management guidelines 
or endorsement of international guidelines by peak professional bodies will provide a useful national 
benchmark for practice. Therapy guidelines can then be developed in a context where standards for 
organisation and processes of spasticity care are clear. 
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Table 1: Demographic Data 
Factor  
(n of 128 respondents 
who answered 
question) 
Categories 
n 
 
% of 
respondents 
 
Profession 
 (n=126)  
Physiotherapist 
Occupational Therapist 
      50 
76 
39.7 
60.3 
Gender(n=127) Female  114 90 
State or Territory  
(All Australian 
jurisdictions listed) 
(n=128) 
 
Australian Capital Territory 
New South Wales 
Northern Territory 
Queensland 
South Australia 
Tasmania 
Victoria 
Western Australia 
1 
43 
0 
10 
7 
11 
45 
11 
1 
33.5 
0 
8 
5.5 
8.5 
35 
8.5 
Geographical Location 
of Current Work Setting 
(n=114)  
 
Capital City 
Other metropolitan area 
Rural 
Remote 
92 
15 
7 
0 
81 
13 
6 
0 
Primary Work Role 
(n=128) 
 
Clinician 
Manager 
Academic 
Consultant 
Researcher 
110 
8 
4 
3 
3 
86 
6.5 
3 
2 
2 
Primary setting of 
current Practice 
(n=119) 
 
Intensive care unit 
Acute hospital inpatient ward 
Inpatient rehabilitation service 
Outpatient rehabilitation service 
Community rehabilitation service 
Day Hospital 
Private Practice  
University clinical research  
Spasticity Clinic (in or outpatient not 
specified) 
Both in and outpatient service 
0 
10 
41 
35 
22 
4 
3 
2 
1 
 
1 
0 
8.5 
34.5 
29.5 
18.5 
3.5 
2.5 
2 
1 
 
1 
Number of BoNT-A 
patients worked with in 
career 
(n=128) 
 
 
<5 
5-10 
11-20 
21-30 
>30 
36 
37 
21 
11 
25 
28 
29 
16.5 
8.5 
19.5 
Patients in neurology 
caseload who received 
BoNT-A injection 
(n=109) 
<1 
1 to <5% 
5% 
<10% 
10% 
20 25% 
30% 
40% 
6  
26 
23 
6  
22  
11  
5  
1  
5.5 
24 
21 
5.5 
20 
10 
4.5 
1 
70% 
95% 
N/A 2 
Comment made no % estimate given 
2  
2  
2  
3  
2 
2 
2 
2.5 
 
Table 2: Organisation and process of care  
Factor 
(n of 128 participants 
responding) 
 
Category n % of 
respondents 
Setting: Service type for 
injection 
(n=128) 
BoNT-A spasticity Clinic – public hospital  
BoNT-A spasticity Clinic- private hospital  
BoNT-A spasticity Clinic – private community 
service (not hospital) 
Public hospital doctor – not in a BoNT-A 
clinic 
Private hospital doctor – not in a BoNT-A 
clinic 
Private provider – not in a BoNT-A clinic 
Other (Department Veterans Affairs 
provider; mixed private public) 
92 
2 
1 
 
24 
 
5 
 
2 
 
2 
72 
1 
1 
 
20 
 
4 
 
1 
 
1 
Setting: Percentage of 
patients who received 
their injection in a 
multidisciplinary clinic 
situation (ie injecting 
doctor and OT/Physio) 
(n=107) 
 
Zero 
<1 
1 to 5% 
10% 
20 to 25% 
30% 
50% 
70-75% 
80-85% 
90-95% 
100% 
Don’t know 
Not Applicable 
Student Clinic 
25  
1  
3  
3  
4  
4  
8  
3  
8  
15  
30  
1  
1  
1  
23 
1 
3 
3 
3.5 
3.5 
7.5 
3 
7.5 
14 
28 
1 
1 
1 
 
Service: Percentage of 
patients who only see a 
private 
consultant/doctor at 
the time of injection 
(n=106) 
Zero 
<1 to 1% 
5% 
10 to 15% 
20% 
30 to 40% 
50 to 60% 
70 to 75% 
80% 
90 to 95% 
100% 
Don’t know 
Not applicable 
35 
2 
6 
12 
7 
2 
6 
5 
3 
6 
16 
5 
1 
33 
2 
5.5 
11 
6.5 
2 
5.5 
5 
3 
5.5 
15 
5 
1 
Service: Timing of 
physician referral to 
therapy  
(n=85) 
“Blanket” referral (anytime) 
Sometimes before injection 
Sometimes after injection 
Sometimes before or after - no pattern 
Usually before injection 
Usually after injection 
19 
5 
8 
10 
3 
2 
23 
6 
9.5 
12 
3.5 
2.5 
Usually before or after - no pattern 
No referral for treatment 
30 
8 
35.5 
9.5 
Service: Timing of 
therapy assessment in 
relation to injection  
(n=90) 
Usually before injection only 
Usually after injection only 
Usually Before and after injection 
Only sometimes  
Never 
5 
6 
60 
13 
6 
5.5 
7 
67.5 
14.5 
5.5 
Service: Physician use 
of therapy assessment 
findings to decide 
where to inject 
(n=90) 
Yes always 
Yes sometimes 
Rarely 
Never 
Don’t know 
30 
31 
17 
6 
6 
33.3 
34.4 
18.9 
6.7 
6.7 
Service: Timing of 
therapy goals setting in 
relation to injection  
(n=83) 
With patients before injection 
With patients after injection 
With patients but in no particular pattern 
Without patients before injection 
Without patients after injection 
I do not set goals 
56 
9 
16 
2 
0 
0 
68.5 
11 
18 
2.5 
0 
0 
Service: Percentage of 
BoNT-A therapy 
patients who have pre-
injection goal setting 
for  
(n=86) 
Zero 
<5 to 5% 
20 to 25% 
30 to 40% 
50% 
60 to 65% 
70 to 75%% 
80% 
90 to 95% 
99 to 100% 
Not applicable  
7 
8 
4 
2 
5 
2 
11 
10 
7 
29 
1 
8 
9 
4.5 
2 
6 
2.5 
13 
11.5 
8 
34 
1 
 
 
Table 3: Issues related to therapy access 
Issue Example Participant comment 
Shared care 
not  
implemented  
 
Physicians inject without referring 
to therapy 
Some doctors injecting in private room or individual consults do not 
refer on 
Physicians inject and refer to 
therapy after 
I often get client[s] referred to me after injections have been done by 
a private doctor, where by no client goal setting has been done.  
Physicians inject without 
consulting team 
At times the Dr's have been known to inject pt's [sic] on our wards 
with NIL communication with allied health staff.  
 Physician beliefs about utility of 
therapy 
I do not believe our Dr's feel that injected pt's [sic] need intensive 
therapy to get results, and that is a massive barrier. At times Dr's 
have injected different muscles to those recommended by OT/PT - 
we are not always present at injection clinics 
Patient beliefs and expectations It can be viewed by the patient and family, as a quick fix. Not 
something which may need intense therapy and home programs to 
gain the full benefit from 
Post-
injection 
therapy not 
available 
patients 
Injections occur in city; patients 
live in regional areas 
Some patients in regional areas also receive injections whilst in 
Sydney then return to regional area and do not receive follow up 
Injections occur in city and 
patients live in rural areas 
If patients don't live locally, can be … a challenge when many of our 
patients live out of area or in rural areas 
Discharge care destinations may 
not have therapy 
Some are nursing home residents with limited access to therapy 
They may not be in a facility that has PT and OT 
Patients cannot access therapy 
centre 
Some clients don't come into the centre due to access to the centre. 
We do not provide transport unless they cannot make it in with other 
means 
Therapy staff 
inadequate 
for demand 
Waiting lists Sometimes a delay in getting them booked in due to availability 
Short-staffed  PT/OT could be short-staffed  
Competing demands Level of therapy may not be ideal in some situations secondary to 
staffing difficulties within an acute setting  
BoNT-A therapy unavailable These [therapy services] are quite sparse and I doubt they receive 
the intensity they should 
No funding for therapy In our District we currently have no funding for allied health 
Patient prioritizing We are getting to the stage where we would never be able to see 
any other clients if we continued to see the BoNT-A clients forever. 
So we are deciding who benefits from [follow-up] treatment by 
looking at newly referred clients in assessment sessions preBoNT-A. 
Coordinated 
goal directed 
care not 
implemented 
 BoNT-A injection needs 
coordinated follow-up 
BoNT-A without follow up (at least advice) is a waste of time for UL 
unless it is something really simple like pain relief - which it rarely is 
Goal directed multidisciplinary care 
impeded 
Rehab consultant … He does not include allied health prior to or 
during BoNT-A injections so we never get to look at the patient from 
a team perspective to see … what the goals might be 
 Maximise gains of BoNT-A with 
therapy 
If there is enough clinical evidence to provide BoNT-A in the first 
place then there are gains to be made for the client and these should 
be maximised by therapeutic intervention - preferably a combination 
of OT and PT to ensure gains are made in muscle length, muscle 
strength, movement patterns, splinting is provided and as well as 
placing this into functional movement patterns and translated into 
task performance 
Table 4: Muscles Injected 
Muscle 
N=91 responses 
Rank of injection 
frequency  
(lowest=1 to 
highest=20)* 
Never injected 
(n of 91) 
Don’t Know 
(n of 91) 
Subscapularis 1 37 26 
Rhomboids 1 46 17 
Levator scapulae 2 38 27 
Teres minor and infraspinatus 3 41 17 
Extensor Digitorum 4 45 15 
Extensor carpi radialis longus or brevis 5 43 17 
Extensor carpi ulnaris 5 44 16 
Latissimus dorsi 6 38 19 
Extensor pollicus longus or brevis 7 40 15 
Supinator 7 33 14 
Opponens pollicis 8 26 17 
Teres Major 8 29 17 
Triceps 9 28 9 
Abductor pollicus longus 10 26 15 
Lumbricals 11 21 10 
Adductor pollicus brevis 12 18 14 
Pronator quadratus 13 13 15 
Pronator teres 14 12 11 
Pectoralis major 15 10 3 
Flexor pollicis brevis or longus 16 5 8 
Flexor carpi ulnaris 17 3 6 
Flexor carpi radialis 17 3 7 
Brachioradialis 18 2 8 
Brachialis 19 2 8 
Flexor digitorum profundus or 
superficialis 
19 4 7 
Biceps 20 1 3 
*If the sum of values was the same for different items, the same rank was used. 
Table 5: Assessment use and perceived relevance 
Assessment Name 
 
 
Rank of least to 
most frequently 
used 
assessment  
Low =1 
High= 26* 
(n=item 
respondents) 
Rank of least 
to most 
relevant 
assessment 
Low =1 
high =27* 
(n=item 
respondents) 
Therapists who 
never use 
assessment 
n (% of 
frequency of 
use n= item 
respondents ) 
 
Therapists who 
have never 
heard of 
assessment 
n (% of 
frequency of 
use n= item 
respondents ) 
Therapists 
unable to judge 
relevance of 
assessment  
n (% of 
relevance rating 
n=item 
respondents) 
Penn Spasm Scale  1 (82) 4 (78) 28 (34)  53 (65.5) 67 (86)  
London Handicap Scale 2 (81) 2 (80) 26 (32) 54 (66.5) 69 (86) 
Re-integration to Normal 
Living Index 
2 (82) 6 (78) 33 (40) 46 (56) 65 (83)  
Rankin Scale 3 (80) 4 (78) 49 (61.5) 28 (35) 63 (81) 
Warrtenberg Pendulum 
Test 
3 (82) 1 (79)  26 (32) 54 (66)  71 (90) 
Patient Rated Wrist 
Evaluation 
4 (83) 3 (77)  32 (38.5) 48 (58) 66 (85.5)  
Wolf  Motor Function Test 5 (82) 7 (78) 39 (47.5) 39 (47.5) 60 (77) 
ArMA Activity Measure 5 (81) 5 (80) 26 (32) 51 (63) 71 (89) 
Assessment of Motor and 
Process Skills (AMPS) 
6 (78) 9 (78) 57 (73) 16 (20.5) 52 (66.5)  
Box and Block 6 (81) 8 (78) 43 (53) 32 (39.5) 56 (72) 
Motor Activity Log 7 (81) 10 (77) 44 (54.5) 29 (36) 55 (72)  
Spasm Frequency Scale 8 (83) 8 (77)  30 (36) 44 (53) 57 (74) 
Range of Motion- Torque-
Controlled Goniometry 
9 (82)  12 (77) 54 (66) 15 (1.5) 43 (56)  
Disabilities of the Arm, 
Shoulder and Hand 
Questionnaire (DASH) 
10 (80) 11 (79) 43 (54) 19 (24) 52 (66)  
Barthel Index 11 (83)  14 (78) 60 (72) 2 (2.5) 22 (29)  
Action Research Arm Test 12 (82)  13 (79) 39 (47.6) 16 (19.5%) 37 (47) 
Purdue Peg Board 13 (83) 15 (78) 40 (48) 11 (13) 32 (41) 
Ashworth Scale 14 (83) 16 (80) 44 (53) 1 (1) 25 (31.5) 
Canadian Occupational 
Performance Measure 
15 (83)  19 (82) 38 (46) 6 (7.2) 28 (34)  
Nine-Hole Peg Test 16 (82) 18 (76) 30 (36.5) 5 (6) 16 (21)  
Functional Independence 
Measure 
17 (84)  18 (80) 41 (49) 3 (3.5) 10 (12.5) 
Goal Attainment Scale 18 (84)  25 (80) 24 (28.6) 3 (3.5) 8 (10) 
Pain Visual Analogue 
Scale 
19 (83)  23 (79) 14 (17) 5 (6) 9 (11.5) 
Motor Assessment 
Scale(MAS) or UL MAS 
20 (86) 20 (80) 19 (22) 2 (2.5) 12 (15)  
Modified Tardieu Scale 21 (84)  22 (79) 15 (18) 8(9.5) 15 (19) 
Manual Muscle test 
(muscle strength rating) 
22 (84)  21 (78) 11 (13) 2 (2.5) 5 (6.5)  
Tardieu Scale 23 (87)  26 (79) 26 (30) 0 (0) 9 (11.5)  
Modified Ashworth Scale 24 (85) 24 (82) 9 (10.5) 1 (1) 6 (7.5)  
Range of Motion- 
Goniometry 
26 (88)  27 (80) 7 (8) 0 (0) 4 (5)  
*Derived from sum of response values; equal sum scores given equal rank 
 Action Research Arm Test: Hsieh CL, Hsueh IP, Chiang FM & Lin PH. (1998). Inter-rater 
reliability and validity of the Action Research Arm test in stroke patients. Age & Ageing 27:107-14. 
Arm Activity Measure*: Ashford S,  Slade M, Turner-Stokes L. (2013) Conceptualisation and 
development of the arm activity measure (ArmA) for assessment of activity in the hemiparetic arm. 
Disability and Rehabilitation. (2013) DOI: 10.3109/09638288.2012.743602 
Arm Activity Measure*: Ashford, S. Slade, M. Turner-Stokes, L. (2010) Development of the 
Arm Activity measure (ArmA) for assessment of activity in the hemiplegic arm. Chartered Society of 
Physiotherapy Congress. Liverpool, October 15-16. 
 Ashworth Scale : Ashworth B (1964). Preliminary trial of carisoprodol in multiple sclerosis. 
Practitioner  192:540-542 
Ashworth Scale: Damiano DL, Quinlivan JM, Owen BF, Payne P, Nelson KC, Abel MF 
(2002). What does the Ashworth Scale really measure and are instrumented measures more valid 
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